601 related articles for article (PubMed ID: 31018667)
1. Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel.
Xu K; Ye S; Zhang S; Yang M; Zhu T; Kong D; Chen J; Xu L; Li J; Zhu H; Wang F; Yang L; Zhang J; Fan Y; Ying L; Hu X; Zhang X; Chan NC; Li C
Circ Cardiovasc Interv; 2019 May; 12(5):e007019. PubMed ID: 31018667
[TBL] [Abstract][Full Text] [Related]
2. Impact of Insulin Receptor Substrate-1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention.
Zong J; Tang Y; Wang T; Ullah I; Xu K; Wang J; Chen P; Chen Z; Zhu T; Chen J; Li J; Wang F; Yang L; Fan Y; Shi L; Gong X; Eikelboom JW; Zhao Y; Li C
J Am Heart Assoc; 2022 Aug; 11(16):e025058. PubMed ID: 35929455
[TBL] [Abstract][Full Text] [Related]
3. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
[TBL] [Abstract][Full Text] [Related]
4. Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
Kessler T; Wolf B; Eriksson N; Kofink D; Mahmoodi BK; Rai H; Tragante V; Åkerblom A; Becker RC; Bernlochner I; Bopp R; James S; Katus HA; Mayer K; Munz M; Nordio F; O'Donoghue ML; Sager HB; Sibbing D; Solakov L; Storey RF; Wobst J; Asselbergs FW; Byrne RA; Erdmann J; Koenig W; Laugwitz KL; Ten Berg JM; Wallentin L; Kastrati A; Schunkert H
Cardiovasc Res; 2019 Aug; 115(10):1512-1518. PubMed ID: 30768153
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.
Lewis JP; Ryan K; O'Connell JR; Horenstein RB; Damcott CM; Gibson Q; Pollin TI; Mitchell BD; Beitelshees AL; Pakzy R; Tanner K; Parsa A; Tantry US; Bliden KP; Post WS; Faraday N; Herzog W; Gong Y; Pepine CJ; Johnson JA; Gurbel PA; Shuldiner AR
Circ Cardiovasc Genet; 2013 Apr; 6(2):184-92. PubMed ID: 23392654
[TBL] [Abstract][Full Text] [Related]
6. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
[TBL] [Abstract][Full Text] [Related]
7. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Verdoia M; Daffara V; Pergolini P; Rolla R; Marino P; Bellomo G; Carriero A; De Luca G;
Vascul Pharmacol; 2017 Aug; 93-95():42-47. PubMed ID: 28433569
[TBL] [Abstract][Full Text] [Related]
9. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
10. Serum uric acid level negatively correlated with the prevalence of clopidogrel low response in patients undergoing antiplatelet treatment with aspirin and clopidogrel.
Wang J; Abdus S; Tan C; Gu Q; Yang M; Wang G; Shi L; Gong X; Li C
Nutr Metab Cardiovasc Dis; 2020 Nov; 30(12):2215-2220. PubMed ID: 32912788
[TBL] [Abstract][Full Text] [Related]
11. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
12. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
[TBL] [Abstract][Full Text] [Related]
13. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
[TBL] [Abstract][Full Text] [Related]
14. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
[TBL] [Abstract][Full Text] [Related]
15. Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.
Mangiacapra F; Bressi E; Colaiori I; Ricottini E; Cavallari I; Capuano M; Viscusi MM; Spoto S; Barbato E; Di Sciascio G
J Cardiovasc Transl Res; 2020 Aug; 13(4):668-675. PubMed ID: 31732918
[TBL] [Abstract][Full Text] [Related]
16. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
[TBL] [Abstract][Full Text] [Related]
17. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
[TBL] [Abstract][Full Text] [Related]
18. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL
Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
